Alloy Therapeutics
Latest round
- Series E
Last raised
- Mar 2026
Total raised
- $147M
Investors
- 11
About Alloy Therapeutics
, based in Waltham, US, specializes in innovative antibody discovery and development solutions aimed at accelerating therapeutic drug development for various diseases. Founded in 2017 in Waltham, Massachusetts, Alloy Therapeutics, Inc. is engaged in antibody discovery and development services.Alloy Therapeutics specializes in antibody discovery and development services, offering a comprehensive suite of integrated solutions designed to expedite the therapeutic drug discovery process. Their core product offerings include in vivo discovery platforms and services for monoclonal and bispecific antibodies, alongside specialized capabilities in TCRm antibodies that target intracellular peptides presented on MHC complexes. The company’s Anticlastic™ antisense format is engineered for enhanced potency and safety, addressing key challenges in the development of antisense oligonucleotide (ASO) drug candidates. Their platforms serve a diverse client base that includes biotechnology and pharmaceutical companies across North America, Europe, and Asia, focusing on therapeutic applications in oncology and infectious diseases.Alloy Therapeutics operates a B2B model, engaging with partners and clients through collaborative agreements and service contracts. Transactions typically involve comprehensive service packages that incorporate various stages of drug discovery, from initial antibody discovery to lead optimization. Pricing structures are situated around partnerships that leverage their proprietary technology platforms, including their flagship offerings such as Keyway™ TCRm discovery and Anticlastic™ antisense molecules. The company emphasizes collaborative innovation, allowing clients to utilize their vast expertise and advanced technologies in drug development projects. Revenue generation occurs through these strategic partnerships, enhancing the overall therapeutic index and delivery mechanisms for their clients' drug candidates. In April 2026, Alloy Therapeutics, Inc.
Who invested in Alloy Therapeutics
11 investors across 3 rounds
See all investors in Alloy Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Alloy Therapeutics
Who invested in Alloy Therapeutics?
Alloy Therapeutics has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alloy Therapeutics raised?
Alloy Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Alloy Therapeutics last raise money?
Alloy Therapeutics's most recent round on record is a Series E, in Mar 2026.
What does Alloy Therapeutics do?
, based in Waltham, US, specializes in innovative antibody discovery and development solutions aimed at accelerating therapeutic drug development for various diseases.
Where is Alloy Therapeutics headquartered?
Alloy Therapeutics is headquartered in Waltham, US.
Which VCs invest in companies like Alloy Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Alloy Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Alloy Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.